Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,990,000 shares, a decrease of 9.1% from the February 13th total of 2,190,000 shares. Based on an average daily volume of 381,800 shares, the days-to-cover ratio is presently 5.2 days. Approximately 3.6% of the shares of the stock are short sold.
Aldeyra Therapeutics Stock Up 12.0 %
Shares of NASDAQ ALDX opened at $7.86 on Wednesday. Aldeyra Therapeutics has a 12-month low of $2.36 and a 12-month high of $8.00. The firm’s 50-day simple moving average is $6.67 and its 200 day simple moving average is $6.17. The company has a quick ratio of 11.78, a current ratio of 11.78 and a debt-to-equity ratio of 0.10. The company has a market cap of $460.28 million, a price-to-earnings ratio of -7.42 and a beta of 1.07.
Analyst Ratings Changes
Several equities analysts recently issued reports on ALDX shares. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Aldeyra Therapeutics in a report on Friday, March 10th. Citigroup lifted their target price on shares of Aldeyra Therapeutics from $23.00 to $28.00 in a research note on Friday, March 10th.
Hedge Funds Weigh In On Aldeyra Therapeutics
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
- Get a free copy of the StockNews.com research report on Aldeyra Therapeutics (ALDX)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.